Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas - Interim financial report, first quarter 2019

Vestas Wind Systems A/S, Aarhus, 8 May 2019Company announcement No. 09/2019 Summary: Revenue on par with last year’s first quarter while earnings and free cash flow decreased. Solid order intake and combined order backlog at all-time high level. Guidance for 2019 maintained.  In the first quarter of 2019, Vestas generated revenue of EUR 1,730m – an increase of 2 percent compared to the year-earlier period. EBIT before special items decreased by EUR 83m to EUR 43m. The EBIT margin was 2.5 percent compared to 7.4 percent in the first quarter of 2018 and free cash flow* amounted to EUR

Nordstjernan acquires shares in Attendo from Pertti Karjalainen

Nordstjernan has acquired 2,221,930 shares for a total consideration of approximately SEK 111 million from Pertti Karjalainen, CEO Attendo Finland, who wants to reduce his debt position. Following the transaction, Nordstjernan’s ownership in Attendo amounts to 17.3 percent of the capital and voting rights, and Karjalainen’s ownership in Attendo amounts to 12.8 percent of the capital and voting rights. The consideration per share has been calculated based on the volume-weighted average share price during the last 15 trading days. Tomas BillingCEONordstjernan AB Questions will be

BioGaia AB Interim management statement 1 January – 31 March 2019

Comments from the CEO:Sales during the first quarter increased by 9% (excluding foreign exchange effects, 2%) compared to the corresponding period last year. Sales of products, excluding royalty revenues, increased by 19% (excluding foreign exchange effects, 11%). Our largest product, BioGaia Protectis baby drops, increased in all markets and our Adult Health portfolio, with above all BioGaia Protectis tablets and BioGaia Prodentis lozenges, grew by 54% which is the result of focus on this target group. Sales in the Americas decreased by 9% which is a consequence of quarterly variations.

Trastuzumab deruxtecan demonstrated clinically

8 May 2019 07:00 BST Trastuzumab deruxtecan demonstrated clinically-meaningful response inpatients with refractory HER2-positive metastatic breast cancer, a population with high unmet need Pivotal Phase II DESTINY-Breast01 trial met primary endpoint,supporting global regulatory submission plan to start in H2 2019 AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate (ADC) and potential new medicine

Bergs Timber has signed a letter of intent to acquire Fågelfors Hyvleri

Bergs Timber AB (publ) (”Bergs Timber”) has today signed a letter of intent (the ”Letter of Intent”) with AB Fogelfors Bruk (“Fogelfors Bruk”) regarding a potential acquisition of all shares in Fågelfors Hyvleri AB (“Fågelfors Hyvleri”).The transaction is subject to the signing of a share purchase agreement (“SPA”), conducting a due diligence to the satisfaction of Bergs Timber, financing and board decision. Bergs Timber will make an announcement once the SPA is signed and closing of the transaction is planned to 30 June 2019. The Letter of Intent grants Bergs Timber exclusivity for the

INTERIM REPORT 1 January 2019 – 31 March 2019 for Bergs Timber AB (publ)

· Net sales for the first quarter 2019 amounted to SEK 885 (367) million. The increase mainly relates to the  acquisition of the Norvik operations in the Baltic States and the UK that was completed in May 2018. · Operating profit amounted to SEK 60 (32) million, representing an operating margin of 6.8 (8.7) percent. · Profit after tax was SEK 52 (26) million. Earnings per share, before and after dilution, was unchanged, SEK 0.15 (0.15). · Cash flow from operations amounted to SEK -34 (38) million and capital expenditures amounted to SEK 35 (10) million. The cash flow was negatively

Discussions on a merger between NextCell AB and Idogen AB are suspended

The discussions that took place between the boards of NextCell Pharma AB ("NextCell") and Idogen AB ("Idogen") (together "The Companies"), regarding a possible merger, are suspended. Although the discussions have been characterized by pragmatism, but the boards of the companies have concluded that both companies will benefit from continuing to pursue their own activities.Even though the discussions regarding a possible merger have now been suspended, the companies choose to continue discussions on how the companies could further cooperate in the future. "We saw it as commercially logica

Norway Royal Salmon: Invitation to presentation of Q1 2019

Norway Royal Salmon will present the interim report for the 1st quarter 2019 on Tuesday 21st May 2019 at hrs 08:00 CET at Hotel Continental, Stortingsgaten 24/26 in Oslo. The company’s CEO Charles Høstlund and CFO Ola Loe will announce the results. Please note that the quarterly report and presentation will be published at 06:30 CET. For further information, please contact:CFO Ola LoeTlf: +47 911 79 411E-mail: ola.loe@salmon.no

Interim report January-March 2019

· Profit from property management attributable to parent company shareholders amounted to SEK 901m (683), corresponding to an increase per share by 32 % to SEK 5.01 (3.80) · Long term net asset value amounted to SEK 288.74 per share (237.48)  · Rental income amounted to SEK 1,797m (1,573) · Profit after tax attributable to parent company shareholders amounted to SEK 1,188m (2,015) corresponding to SEK 6.60 per share (11.20)  Profit from property management for the period amounted to SEK 1,046m (815). Profit from property management attributable to parent company

INTERIM REPORT 1 JANUARY – 31 MARCH 2019

First quarter in brief  · Net sales for the quarter amounted to MSEK 81 (55). · Operating profit/loss before depreciation and amortisation excluding associates (adjusted EBITDA) amounted to MSEK 40 (30), and including associates totalled MSEK -232 (30). · Operating profit/loss excluding associates (adjusted EBIT) amounted to MSEK 21 (12), and including associates EBIT was MSEK -251 (12). · Profit/loss before tax excluding associates (adjusted EBT) totalled MSEK -3 (-16), and including associates (EBT) was MSEK -294 (-16). · Profit/loss after tax excluding associates (

Interim report January-March 2019

Improved earnings and higher rate of growth · Net sales for the period amounted to SEK 5,207m (4,530), an increase of 14% (2) adjusted for acquisitions and divestments · Several of Ratos’s companies demonstrated both increased net sales and an improved order situation · EBITA, excluding IFRS 16, improved to SEK 44m (-19) · For the rolling 12-month period, earnings from the company portfolio amounted to SEK 895m (838) · Operating profit according to IFRS amounted to SEK 27m (-39) · The board has decided on a new dividend policy At 10.00 CET a telephone conference will

Zalaris sets profitability target and action plan for 2019

Zalaris' Q1/19 revenues reached NOK 192.4 million, a 3% growth compared to Q1/18. Several group-wide actions have been identified to improve on the 3% EBIT-margin achieved in the first quarter, and a target margin of 10% has been set for Q4/19. The first quarter of 2019 is marked by continued revenue growth and the successful launch of new contracts with top-tier clients, but also profitability below target levels. “We aim to continue being a growth company. However, our short-term priority is to return to the margin level that we had prior to our acquisitions – and our target is to

Outokumpu – Transfer of the company’s own shares

Outokumpu OyjStock exchange releaseMay 8, 2019 at 9.00 am EEST Outokumpu – Transfer of the company’s own shares The number of the treasury shares held by Outokumpu has decreased by 79,186 shares. The reduction of the treasury shares is due to the share rewards paid today. After the change, Outokumpu holds 5,069,247 treasury shares. Trading code: OUT1VNumber of shares: 79,186Price/share: Gratuitous For more information: Investors: Tommi Järvenpää, VP, Investor Relations, tel. +358 9 421 3466, +358 40 576 0288 Media: Corporate communications, tel. +358 9 421 3840

Outotec's interim report January-March 2019

OUTOTEC OYJ INTERIM REPORT MAY 8, 2019 AT 9:00 AM  INTERIM REPORT JANUARY-MARCH 2019   Positive signs in greenfield investments and good growth in Services "The overall market sentiment developed positively in the first quarter. In addition to brownfield investments, we are seeing signs of increased greenfield investments in both minerals processing and metal refining technologies. Order intake was at the same good level as in the first quarter last year. I am pleased with the 22% growth in service orders and the 19% increase in equipment orders for Minerals Processing. Sales

A NEW ERAS[®] PROTOCOL FOR BREAST RECONSTRUCTION IS NOW AVAILABLE IN THE ERAS[®] INTERACTIVE AUDIT SYSTEM

New ERAS[®] Protocol for Breast Reconstruction, based on the published ERAS[® ]Society Guidelines: Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery After Surgery (ERAS) Society Recommendations. Read more here . The ERAS[®] Interactive Audit System is now available including Protocols for the surgical areas of Colorectal, Gynecology, Urology/Cystectomy, Pancreas, Liver, Head & Neck, Bariatric and Breast Reconstruction. Please contact us  for details on how to

Karnov Group reports first quarter results 2019

Continued growth with improved profitabilityFirst quarter summary ·  Net sales up 6% to SEK 205 m (194) and organic growth of 3%. ·  EBITA increased by SEK 26 m to SEK 67 m (41) with EBITA margin of 32.9% (21.2%), mainly due to SEK 17 m lower impact from items affecting comparability. ·  Adjusted EBITA increased by 12% to SEK 85 m (76) and adjusted EBITA margin improved by 2 percentage points to 41.6% (39.2). ·   Operating profit (EBIT) increased to SEK 37 m (12). ·   Earnings per share before and after dilution increased to SEK 0.07 (-0.23). ·  Operating cash flow

High pace in the adjustment process

· Net sales increased with 3 % to SEK 253 million (244). · EBIT amounted to SEK 13.5 million (21.0), corresponding to a margin of 5.4 (8.6) %. · Earnings per share amounted to SEK 0.01 (0.37). · The average income per member and month increased with 6 per cent to SEK 374 (353).In today’s interim report, Actic Group reports a growth of 3 % in the first quarter of 2019. EBIT amounted to SEK 13.5 million with a margin of    5.4 %. The average income per member and month (ARPM) increased with 6 % to SEK 374. “Although we saw growth in revenue from gym cards and growth in the average

Endomines’ AB Q1 2019 Business review – Focus on the Friday mine

Endomines AB, Stock Exchange Release 8 May 2019 at 07:45 CEST Q1 2019 (vs Q1 2018)   Operational highlights · The focus of operational activity was on mine development and construction of the processing plant at the Friday mine in Idaho, USA · There was no gold concentrate production in Q1 2019 · LTIFR 12 (8) Financial highlights · Revenue was 2.1 MSEK (29.4) · EBITDA was -11.5 MSEK (-8.5) · Total cash flow was -11.2 MSEK (87.1) · Earnings per share was -0.37 SEK (0.06) SIGNIFICANT SUBSEQUENT EVENTS · The Board of Directors announced on 3 May 2019

Lindab International AB (publ): Lindab's Interim Report for the First Quarter 2019

First quarter 2019 · Net sales increased by 8 percent to SEK 2,315 m (2,153), of which organic growth was 5 percent. · Adjusted[1)] operating profit increased by 85 percent to SEK 192[2)] m (104). Adjusted[1)] operating margin increased to 8.3 percent (4.8). · Operating profit amounted to SEK 192[2)] m (71). · Profit for the period increased to SEK 142 m (46). · Earnings per share, before and after dilution, increased to SEK 1.85 (0.60). · Cash flow from operating activities amounted to SEK 79[2)] m (42). · On January 1, 2019, Lindab implemented a new

Storebrand Livsforsikring AS: Interim report 1st quarter 2019

Storebrand Livsforsikring AS is a wholly owned subsidiary of the listed company Storebrand ASA. For information about the Storebrand Group's Q1 2019 result and Balance sheet statement, please refer to the Storebrand Group Q1 2019 interim report. Storebrand Livsforsikring AS Group's interim report for Q1 2019 is attached. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Apetit Plc’s Business Review 1 January – 31 March 2019: Apetit’s operational EBIT improved thanks to Food Solutions; poor harvest still influencing Grain Trade profitability

Apetit Plc, Stock Exchange Release, 8 May 2019 at 8.30 a.m.JANUARY–MARCH 2019 IN BRIEF  January–March 2019  ·  Net sales amounted to EUR 76.4 (59.7) million  ·  Operational EBITDA was EUR 1.8 (0.6) million  ·  Operational EBIT was EUR 0.3 (-0.8) million  The information is unaudited. The figures in parentheses are the equivalent figures for the same period in 2018, and the comparison period means the corresponding period in the previous year, unless otherwise stated.  Juha Vanhainen, CEO:  “Performance at the beginning of the year continued to be held back by the

Altia Plc January-March 2019: Stable net sales development, timing of Easter and high raw material costs impacted profitability

Altia Plc Stock Exchange Release 8 May at 8:30 am EET Altia Plc Business Review January-March 2019: Stable net sales development, timing of Easter and high raw material costs impacted profitability This release is a summary of Altia Plc's Business Review January-March 2019. The complete report is attached to this release and is also available on the company website at www.altiagroup.com/investors. January–March 2019 compared to January–March 2018 · Reported net sales were EUR 73.8 (73.5) million · In constant currencies, net sales grew by 1.3% in comparison to previous year

There are no items matching the current filter
There are no more items matching the current filter
Back to top